


Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of the claims in the application:

Listing of Claims:

1. – 77. (cancelled)

78. (new) A pharmaceutical or cosmetic composition comprising at least one of a pharmaceutically or cosmetically acceptable carrier and a pharmaceutically or cosmetically acceptable adjuvant and at least one active ingredient selected from compounds of formulae C1 to C17, including tautomers, stereoisomers thereof, pharmaceutically acceptable salts, salt derivatives, tautomers and stereoisomers thereof:




C1

wherein

- X and Z are identical or different and are independently selected from hydroxy, thiol, C₁- to C₁₂ alkoxy, C₁- to C₁₂ alkylthio, unsubstituted or substituted, uncondensed or condensed aryl and cycloalkyl optionally containing one or several heteroatoms from the group of N, O, P and S, and amino (NH₂, NHR², NR²R³);


- Y represents O, S or NR₄;
- R₁, R₂, R₃ and R₄ are identical or different and are selected from hydrogen, unsubstituted or substituted, straight chain or branched C₁- to C₁₂ alkyl, C₂- to C₁₂ alkenyl and C₂- to C₁₂ alkynyl, hydroxy, thiol, C₁- to C₁₂ alkoxy, C₁- to C₁₂ alkylthio, unsubstituted or substituted, uncondensed or condensed, aryl and cycloalkyl optionally containing one or several heteroatoms selected from N, O, P and S, unsubstituted or substituted amino, unsubstituted or substituted carbonyl, unsubstituted or substituted thiocarbonyl and unsubstituted or substituted imino; and
- heteroaromatic or heterocyclic residues are bound to a basic structure of formula C1 via a C atom or a heteroatom;



wherein


- R₁ to R₄ are identical or different and are selected from hydrogen, unsubstituted or substituted, straight chain or branched C₁- to C₁₂ alkyl, C₂- to C₁₂ alkenyl and C₂- to C₁₂ alkynyl, hydroxy, thiol, C₁- to C₁₂ alkoxy, C₁- to C₁₂ alkylthio, unsubstituted or substituted, uncondensed or condensed aryl and cycloalkyl optionally containing one or several heteroatoms selected from N, O, P and S, unsubstituted or substituted amino, unsubstituted or substituted carbonyl, unsubstituted or substituted thiocarbonyl and unsubstituted or substituted imino; and

- heteroaromatic or heterocyclic residues are bound to a basic structure of formula C2 via a C atom or a heteroatom;



wherein


- R1, R2 and R3 are identical or different and are selected from hydrogen, unsubstituted or substituted, straight chain or branched C₁- to C₁₂ alkyl, C₂- to C₁₂ alkenyl and C₂- to C₁₂ alkynyl, hydroxy, thiol, C₁- to C₁₂ alkoxy, C₁- to C₁₂ alkylthio, unsubstituted or substituted, uncondensed or condensed aryl and cycloalkyl optionally containing one or several heteroatoms selected from N, O, P and S, unsubstituted or substituted amino, unsubstituted or substituted carbonyl, unsubstituted or substituted thiocarbonyl and unsubstituted or substituted imino; and
- heteroaromatic or heterocyclic residues are bound to a basic structure of formula C3 via a C atom or a heteroatom;




wherein

- X1, X2, X3 and X4 are identical or different and represent CH or CR₃ units;


- Y1, Y2 and Y3 are identical or different and represent substituted or unsubstituted carbon atom or heteroatom units having N, O, P or S ring atoms;
- R1 and R2 symbolize a substitution pattern of a respective partial ring, wherein R1 represents one to four identical or different substituents and R2 represents one to six identical or different substituents, which substituents are selected from hydrogen, unsubstituted or substituted, straight chain or branched C₁- to C₁₂ alkyl, C₂- to C₁₂ alkenyl and C₂- to C₁₂ alkynyl, hydroxy, thiol, C₁- to C₁₂ alkoxy, C₁- to C₁₂ alkylthio, unsubstituted or substituted, uncondensed or condensed aryl and cycloalkyl optionally containing one or several heteroatoms selected from N, O, P and S, unsubstituted or substituted amino, unsubstituted or substituted carbonyl, unsubstituted or substituted thiocarbonyl and unsubstituted or substituted imino; and
- heteroaromatic or heterocyclic residues are bound to a basic structure of formula C4 via a C atom or a heteroatom;



(a)



(b)




(c)

C5

wherein

- Y represents O, S, NH or NR₅;

- R1 to R5 may be identical or different and are selected from hydrogen, unsubstituted or substituted, straight chain or branched C₁- to C₁₂ alkyl, C₂- to C₁₂ alkenyl and C₂- to C₁₂ alkynyl, hydroxy, thiol, C₁- to C₁₂ alkoxy, C₁- to C₁₂ alkylthio, unsubstituted or substituted, uncondensed or condensed aryl and cycloalkyl optionally containing one or several heteroatoms from the group N, O, P and S, unsubstituted or substituted amino, unsubstituted or substituted carbonyl, unsubstituted or substituted thiocarbonyl and unsubstituted or substituted imino; and
- heteroaromatic or heterocyclic residues are bound to a basic structure of formula C5 via a C atom or a heteroatom;




wherein

- Y represents O, S, NH or NR₁;
- X and Z are identical or different and are independently selected from hydroxy, thiol, C₁- to C₈ alkoxy, C₁- to C₈ alkylthio, unsubstituted or substituted, uncondensed or condensed aryl and cycloalkyl optionally containing one or several heteroatoms selected from N, O, P and S, and amino (NH₂, NHR₂, NR₂R₃);
- R1 to R3 are identical or different and are selected from hydrogen, unsubstituted or substituted, straight chain or branched C₁- to C₁₂ alkyl,

C₂- to C₁₂ alkenyl and C₂- to C₁₂ alkynyl, hydroxy, thiol, C₁- to C₁₂ alkoxy, C₁- to C₁₂ alkylthio, unsubstituted or substituted, uncondensed or condensed aryl and cycloalkyl optionally containing one or several heteroatoms selected from N, O, P and S, unsubstituted or substituted amino, unsubstituted or substituted carbonyl, unsubstituted or substituted thiocarbonyl and unsubstituted or substituted imino; and

- heteroaromatic or heterocyclic residues are bound to a basic structure of formula C6 via a C atom or a heteroatom;




C7

wherein

- Y represents O, S, NH or NR₄;
- X and Z are identical or different and are independently selected from hydroxy, thiol, C₁- to C₈ alkoxy, C₁- to C₈ alkylthio, unsubstituted or substituted, uncondensed or condensed aryl and cycloalkyl optionally containing one or several heteroatoms selected from N, O, P and S, and amino (NH₂, NHR₅, NR₅R₆);
- R₁ to R₆ are identical or different and are selected from hydrogen, unsubstituted or substituted, straight chain or branched C₁- to C₁₂ alkyl, C₂- to C₁₂ alkenyl and C₂- to C₁₂ alkynyl, hydroxy, thiol, C₁- to C₁₂ alkoxy, C₁- to C₁₂ alkylthio, unsubstituted or substituted, uncondensed or

condensed aryl and cycloalkyl optionally containing one or several heteroatoms selected from N, O, P and S, unsubstituted or substituted amino, unsubstituted or substituted carbonyl, unsubstituted or substituted thiocarbonyl and unsubstituted or substituted imino; and

- heteroaromatic or heterocyclic residues are bound to a basic structure of formula C7 via a C atom or a heteroatom;




C8

wherein

- X represents a N, O, S or P heteroatom or a functional group containing one of these heteroatoms as a ring atom;
- a basic six-membered ring structure of C8 may contain up to three further heteroatoms X, wherein the heteroatoms may be identical or different;
- a basic six-membered ring structure of C8 may contain zero to three double bonds;
- R1 symbolizes a substitution of a basic six-membered ring structure of C8 and represents one to ten substituents;
- R1 is selected from hydrogen, unsubstituted or substituted, straight chain or branched C₁- to C₁₂ alkyl, C₂- to C₁₂ alkenyl and C₂- to C₁₂ alkynyl, hydroxy, thiol, C₁- to C₁₂ alkoxy, C₁- to C₁₂ alkylthio, unsubstituted or substituted, uncondensed or condensed aryl and cycloalkyl optionally containing one or several heteroatoms selected from N, O, P and S,


unsubstituted or substituted amino, unsubstituted or substituted carbonyl, unsubstituted or substituted thiocarbonyl and unsubstituted or substituted imino; and

- heteroaromatic or heterocyclic residues are bound to a basic structure of formula C8 via a C atom or a heteroatom;



wherein

- X1 represents CH₂, CHR₃, CR₃R₄, NH, NR₄, O or S;
- X2, X3 and X4 represent CH, CR₅ or N;
- R1 to R5 are identical or different and are selected from hydrogen, unsubstituted or substituted, straight chain or branched C₁- to C₁₂ alkyl, C₂- to C₁₂ alkenyl and C₂- to C₁₂ alkynyl, hydroxy, thiol, C₁- to C₁₂ alkoxy, C₁- to C₁₂ alkylthio, unsubstituted or substituted, uncondensed or condensed aryl and cycloalkyl optionally containing one or several heteroatoms selected from N, O, P and S, unsubstituted or substituted amino, unsubstituted or substituted carbonyl, unsubstituted or substituted thiocarbonyl and unsubstituted or substituted imino;
- heteroaromatic or heterocyclic residues are bound to a basic structure of formula C9 via a C atom or a heteroatom; and
- a basic six-membered ring structure of formula C9 may contain zero to three double bonds;




C10

wherein

- X and Z represent CH, CR¹ or N and at least one of X and Z represents or comprises a heteroatom of a basic structure;
- partial rings may be substituted or unsubstituted, condensed or noncondensed and may comprise zero to three double bonds and further heteroatoms and heteroatom-containing groups corresponding to definitions for X and Z,
- R¹ is selected from hydrogen, unsubstituted or substituted, straight chain or branched C₁- to C₁₂- alkyl, C₂- to C₁₂ alkenyl and C₂- to C₁₂ alkynyl, hydroxy, thiol, C₁- to C₁₂ alkoxy, C₁- to C₁₂ alkylthio, unsubstituted or substituted, uncondensed or condensed aryl and cycloalkyl optionally containing one or several heteroatoms selected from N, O, P and S, unsubstituted or substituted amino, unsubstituted or substituted carbonyl, unsubstituted or substituted thiocarbonyl and unsubstituted oder substituted imino;
- heteroaromatic or heterocyclic residues are bound to a basic structure of formula C10 via a C atom or a heteroatom; and


- ring systems of basic structures may contain zero to three double bonds;




C11

wherein


- R1 represents a substitution pattern of a basic heteroaromatic structure consisting of up to five identical or different substituents, R1 being selected from hydrogen, unsubstituted or substituted, straight chain or branched C₁- to C₁₂ alkyl, C₂- to C₁₂ alkenyl and C₂- to C₁₂ alkynyl, hydroxy, thiol, C₁- to C₁₂ alkoxy, C₁- to C₁₂ alkylthio, unsubstituted or substituted, uncondensed or condensed aryl and cycloalkyl optionally containing one or several heteroatoms selected from N, O, P and S, unsubstituted or substituted amino, unsubstituted or substituted carbonyl, unsubstituted or substituted thiocarbonyl and unsubstituted or substituted imino; and
- heteroaromatic or heterocyclic residues are bound to a basic structure of formula C11 via a C atom or a heteroatom;



(a)



(b)




(c)

C12

wherein


- Y1 and Y2 are identical or different and represent O, S, NH or NR6;
- R1 to R6 are identical or different and are selected from hydrogen, unsubstituted or substituted, straight chain or branched C₁- to C₁₂ alkyl, C₂- to C₁₂ alkenyl and C₂- to C₁₂ alkynyl, hydroxy, thiol, C₁- to C₁₂ alkoxy, C₁- to C₁₂ alkylthio, unsubstituted or substituted, uncondensed or condensed aryl and cycloalkyl optionally containing one or several heteroatoms from the group N, O, P and S, unsubstituted or substituted amino, unsubstituted or substituted carbonyl, unsubstituted or substituted thiocarbonyl and unsubstituted or substituted imino; and
- heteroaromatic or heterocyclic residues are bound to a basic structure of formula C12 via a C atom or a heteroatom;



C13

wherein


- X and Z are identical or different and are independently selected from hydroxy, thiol, C₁- to C₈ alkoxy, C₁- to C₈ alkylthio, unsubstituted or substituted, uncondensed or condensed aryl and cycloalkyl optionally containing one or several heteroatoms selected from N, O, P and S, and amino (NH₂, NHR₁, NR₁R₂);
- Y represents O, S, NH or NR₃;
- R₁ to R₃ are identical or different and are selected from hydrogen, unsubstituted or substituted, straight chain or branched C₁- to C₁₂ alkyl, C₂- to C₁₂ alkenyl and C₂- to C₁₂ alkynyl, hydroxy, thiol, C₁- to C₁₂ alkoxy, C₁- to C₁₂ alkylthio, unsubstituted or substituted, uncondensed or condensed aryl and cycloalkyl optionally containing one or several heteroatoms selected from N, O, P and S, unsubstituted or substituted amino, unsubstituted or substituted carbonyl, unsubstituted or substituted thiocarbonyl and unsubstituted or substituted imino; and
- heteroaromatic or heterocyclic residues are bound to a basic structure of formula C13 via a C atom or a heteroatom;



wherein

- Y₁ and Y₂ are identical or different and represent O, S, NH or NR₃;

- R1 to R3 are identical or different and are selected from hydrogen, unsubstituted or substituted, straight chain or branched C₁- to C₁₂ alkyl, C₂- to C₁₂ alkenyl and C₂- to C₁₂ alkynyl, hydroxy, thiol, C₁- to C₁₂ alkoxy, C₁- to C₁₂ alkylthio, unsubstituted or substituted, uncondensed or condensed aryl and cycloalkyl optionally containing one or several heteroatoms selected from N, O, P and S, unsubstituted or substituted amino, unsubstituted or substituted carbonyl, unsubstituted or substituted thiocarbonyl and unsubstituted or substituted imino; and
- heteroaromatic or heterocyclic residues are bound to a basic structure of formula C14 via a C atom or a heteroatom;




wherein

- X represents O, S, NH or NR₉;
- R1 to R9 are identical or different and are selected from hydrogen, unsubstituted or substituted, straight chain or branched C₁- to C₁₂ alkyl, C₂- to C₁₂ alkenyl and C₂- to C₁₂ alkynyl, hydroxy, thiol, C₁- to C₁₂ alkoxy, C₁- to C₁₂ alkylthio, unsubstituted or substituted, uncondensed or condensed aryl and cycloalkyl optionally containing one or several heteroatoms selected from N, O, P and S, unsubstituted or substituted

amino, unsubstituted or substituted carbonyl, unsubstituted or substituted thiocarbonyl and unsubstituted or substituted imino; and

- heteroaromatic or heterocyclic residues are bound to a basic structure of formula C15 via a C atom or a heteroatom;




C16

wherein

- R1 to R5 are identical or different and are independently selected from hydrogen, CH₃, CH₂R₆, CHR₆R₇, CR₆R₇R₈, OH, OR₆, NH₂, NHR₆, NR₆R₇, C(O)R₆, C(NH)R₆, C(NR₇)R₆, C(S)R₆, PH₂, PHR₆, P(R₆)R₇, P(O)(OH)₂, P(O)(OH)(OR₆), P(O)(OR₆)(OR₇) and CN;
- A, Y and Z are identical or different and are independently selected from CH₂, CHR₉, CR₉R₁₀, C(O), C(S), C(NH), C(NR₉), NH, NR₉, NOH, NOR₉, O, S, SO₂, PH, PR₉, P(O)OH, P(O)OR₉, P(OH)₃, P(OH)₂POR₉, P(OH)(OR₉)(OR₁₀), P(OR₉)(OR₁₀)(OR₁₁);
- X represents N, CH, CR₁₂, P, P=O, P(OH)₂, P(OH)(OR₁₂) or P(OR₁₂)(OR₁₃);
- R₆ to R₁₃ are identical or different and are independently selected from hydrogen, unsubstituted or substituted, straight chain or branched C₁- to C₁₂ alkyl, C₂- to C₁₂ alkenyl and C₂- to C₁₂ alkynyl, hydroxy, thiol, C₁- to

C₁₂ alkoxy, C₁- to C₁₂ alkylthio, unsubstituted or substituted, uncondensed or condensed aryl and cycloalkyl optionally containing one or several heteroatoms selected from N, O, P and S, unsubstituted or substituted amino, unsubstituted or substituted carbonyl, unsubstituted or substituted thiocarbonyl and unsubstituted or substituted imino;

- heteroaromatic or heterocyclic residues are bound to a basic structure of formula C16 via a C atom or a heteroatom;











wherein








- R1 to R5 are identical or different and are independently selected from hydrogen, CH₃, CH₂R₆, CHR₆R₇, CR₆R₇R₈, OH, OR₆, NH₂, NHR₆, NR₆R₇, C(O)R₆, C(NH)R₆, C(NR₇)R₆, C(S)R₆, PH₂, PHR₆, P(R₆)R₇, P(O)(OH)₂, P(O)(OH)(OR₆), P(O)(OR₆)(OR₇) and CN;
- A represents CH₂, CHR₉, CR₉R₁₀, C(O), C(S), NH, NR₉, NOH, NOR₉, O, S, SO₂, PH, PR₉, P(O)OH, P(O)OR₉, P(OH)₃, P(OH)₂POR₉, P(OH)(OR₉)(OR₁₀), P(OR₉)(OR₁₀)(OR₁₁);
- R6 to R13 are identical or different and are independently selected from hydrogen, unsubstituted or substituted, straight chain or branched C₁- to C₁₂ alkyl, C₂- to C₁₂ alkenyl and C₂- to C₁₂ alkynyl, hydroxy, thiol, C₁- to




C₁₂ alkoxy, C₁- to C₁₂ alkylthio, unsubstituted or substituted, uncondensed or condensed aryl and cycloalkyl optionally containing one or several heteroatoms selected from N, O, P and S, unsubstituted or substituted amino, unsubstituted or substituted carbonyl, unsubstituted or substituted thiocarbonyl and unsubstituted or substituted imino.



79. (new) The composition of claim 78, wherein the composition comprises at least one active ingredient selected from compounds of the following formulae, including tautomers, stereoisomers thereof, pharmaceutically acceptable salts, salt derivatives, tautomers and stereoisomers thereof:






| | |
|--------|--|
| C1.001 |  |
| C1.002 |  |





| | |
|--------|--|
| C1.003 |  |
| C2.001 |  |
| C2.002 |  |
| C2.003 |  |
| C2.004 |  |
| C2.005 |  |





| | |
|--------|--|
| C2.006 |  <chem>COc1cc(Br)ccc1OC(=O)NN=Cc1cc(Br)c(Br)c1=O</chem> |
| C2.007 |  <chem>CC1=CC=C(C=C1)N2C=CC(C)=C2C(=O)NN=Cc1cc(Br)c(Br)c1=O</chem> |
| C2.008 |  <chem>CC1=CC=C(C=C1)NC(=O)NN=Cc1cc(Br)c(Br)c1=O</chem> |
| C2.009 |  <chem>O=C1C(=O)N(C1=CC=C2C(=C(C=C2)OC3OC3)C(=O)NN=Cc4cc(Br)c(Br)c4=O)C(=O)c5ccccc5</chem> |
| C2.010 |  <chem>COc1ccccc1C(=O)NN=Cc1ccoc1C</chem> |
| C2.011 |  <chem>O=C1C(=O)N(C1=CC2=CC=CC=C2C3=CC=CC=C3)NN=Cc4cc(Br)c(Br)c4=O</chem> |
| C2.012 |  <chem>COc1ccc(cc1)C(=O)NN=Cc2cc(Br)c(Br)c2=O</chem> |





| | |
|--------|--|
| C2.013 |  |
| C2.014 |  |
| C2.015 |  |






| | |
|--------|---|
| C3.001 |  |
| C3.002 |  |








| | |
|--------|--|
| C4.008 |  <p>Chemical structure of 1-methyl-2-(2-(pyridin-2-yl)-2-(pyridin-2-ylmethyl)ethyl)indole. The structure features an indole ring with a methyl group at position 1 and a 2-(2-(pyridin-2-yl)-2-(pyridin-2-ylmethyl)ethyl) substituent at position 2.</p> |
| C4.009 |  <p>Chemical structure of 1-methyl-2-(2-(4-fluorophenyl)-2-(pyridin-2-ylmethyl)ethyl)indole. The structure features an indole ring with a methyl group at position 1 and a 2-(2-(4-fluorophenyl)-2-(pyridin-2-ylmethyl)ethyl) substituent at position 2.</p> |
| C4.010 |  <p>Chemical structure of 1-methyl-2-(2-(pyridin-2-yl)-2-(pyridin-2-ylmethyl)ethyl)indole. The structure features an indole ring with a methyl group at position 1 and a 2-(2-(pyridin-2-yl)-2-(pyridin-2-ylmethyl)ethyl) substituent at position 2.</p> |
| C4.011 |  <p>Chemical structure of 1-methyl-2-(2-(pyridin-2-yl)-2-(pyridin-2-ylmethyl)ethyl)indole. The structure features an indole ring with a methyl group at position 1 and a 2-(2-(pyridin-2-yl)-2-(pyridin-2-ylmethyl)ethyl) substituent at position 2.</p> |







| | |
|--------|--|
| C4.012 |  <p>Chemical structure of 2-methyl-3-(2-(pyridin-2-yl)-2-morpholinyl)indole. The structure features an indole ring system with a methyl group at position 2 and a 2-(pyridin-2-yl)-2-morpholinyl group at position 3. The morpholine ring is connected to the indole ring via its nitrogen atom.</p> |
| C4.013 |  <p>Chemical structure of 2-methyl-3-(2-(pyridin-2-yl)-2-azepan-1-yl)indole. The structure features an indole ring system with a methyl group at position 2 and a 2-(pyridin-2-yl)-2-azepan-1-yl group at position 3. The azepane ring is connected to the indole ring via its nitrogen atom.</p> |
| C4.014 |  <p>Chemical structure of 2-methyl-3-(2-(thiophen-2-yl)-2-(carbamoylmethyl)piperidin-1-yl)indole. The structure features an indole ring system with a methyl group at position 2 and a 2-(thiophen-2-yl)-2-(carbamoylmethyl)piperidin-1-yl group at position 3. The piperidine ring is connected to the indole ring via its nitrogen atom, and it has a carbamoylmethyl group attached to the ring.</p> |
| C4.015 |  <p>Chemical structure of 2-methyl-3-(2-(thiophen-2-yl)-2-(ethoxycarbonylmethyl)piperidin-1-yl)indole. The structure features an indole ring system with a methyl group at position 2 and a 2-(thiophen-2-yl)-2-(ethoxycarbonylmethyl)piperidin-1-yl group at position 3. The piperidine ring is connected to the indole ring via its nitrogen atom, and it has an ethoxycarbonylmethyl group attached to the ring.</p> |






| | |
|--------|---|
| C4.016 |  <p>Chemical structure of 1-methyl-2-(4-methoxyphenyl)-3-(pyrrolidin-1-yl)indole. The structure features an indole ring system with a methyl group at position 1, a 4-methoxyphenyl group at position 2, and a pyrrolidin-1-yl group at position 3.</p> <chem>COc1ccc(cc1)C2=C(C3=CC=CC=C3N2)C4CCCN4</chem> |
| C4.017 |  <p>Chemical structure of 1-methyl-2-(thiophen-2-yl)-3-(piperidin-1-yl)indole. The structure features an indole ring system with a methyl group at position 1, a thien-2-yl group at position 2, and a piperidin-1-yl group at position 3.</p> <chem>C1=CC=C(C=C1)C2=C(C3=CC=CC=C3N2)C4=CC=CC=S4C5CCNCC5</chem> |
| C4.018 |  <p>Chemical structure of 1-methyl-2-(thiophen-2-yl)-3-(morpholin-2-yl)indole. The structure features an indole ring system with a methyl group at position 1, a thien-2-yl group at position 2, and a morpholin-2-yl group at position 3.</p> <chem>C1=CC=C(C=C1)C2=C(C3=CC=CC=C3N2)C4=CC=CC=S4C5CCNCCO5</chem> |
| C4.019 |  <p>Chemical structure of 1-methyl-2-(thiophen-2-yl)-3-(pyrrolidin-1-yl)indole. The structure features an indole ring system with a methyl group at position 1, a thien-2-yl group at position 2, and a pyrrolidin-1-yl group at position 3.</p> <chem>C1=CC=C(C=C1)C2=C(C3=CC=CC=C3N2)C4=CC=CC=S4C5CCCN5</chem> |






| | |
|--------|--|
| C5.001 |  <chem>O=C1C=CC(=C1)N(C(=O)N2C=CC(=C2)N=C3C(=O)C=CC3=N=N4C=CC(=C4)Cl)C5=CC=CC=C5</chem> |
| C5.002 |  <chem>O=C1C(=O)C(Cl)(Cl)C(Cl)=C1N=N(C(=O)N2C=CC=CC2)C3=CC=CC=C3</chem> |
| C6.001 |  <chem>O=C1C(F)(F)C(F)(F)C(F)(F)N1N=C2C(=C3C=CC=C3S2)C#N</chem> |
| C6.002 |  <chem>O=C1C(F)(F)C(F)(F)C(F)(F)N1N=C2C(=C3C=CC=C3SC3C)C#N</chem> |
| C7.001 |  <chem>CCOC(=O)C(F)(F)N(C(=O)N1C=CC(=C1)Cl)C2=CC(=C(C=C2)OC)C(F)(F)F</chem> |






| | |
|--------|--|
| C7.002 |  <chem>CCOC(=O)C(C(F)(F)F)(NC(=O)c1ccc(OC)cc1)N2CCCC2=O</chem> |
| C7.003 |  <chem>CCOC(=O)C(C(F)(F)F)(NC(=O)c1ccc(OC)cc1)N2CCOCC2</chem> |
| C7.004 |  <chem>CCOC(=O)C(C(F)(F)F)(NC(=O)c1ccccc1)N2CCOCC2</chem> |






| | |
|--------|--|
| C8.001 |  <chem>O=C1C(=O)c2ccccc2N1C3CCCCC3</chem> |
| C8.002 |  <chem>CN(C)CCNC1=NC2=C(N1C3=CC=CC=C3Cl)C(=O)N(C)C2=O</chem> |






| | |
|--------|---|
| C8.003 |  <chem>CCOC(=O)C1=CC2=C(N1)N=CN=C2SC1C(=O)OC(C)C</chem> |
| C8.004 |  <chem>CCOC(=O)C1=CC2=C(N1)N=CN=C2SC1C(=O)OC</chem> |
| C8.005 |  <chem>CCOC(=O)C1=CC2=C(N1)N=CN=C2SC1C(=O)N#C</chem> |
| C8.006 |  <chem>CC1=CC=C(C=C1)[N+](=O)[O-]C2=CC=CC=C2C3=CC=CC=C3C4=CC(=C5C(=C4)C(=O)N(CCCOC)C(=O)C5=C6N#CC=C6)C=C3</chem> |
| C8.007 |  <chem>ClC1=CC=C(C=C1)C2=CC=CC=C2C3=CC=CC=C3C4=CC(=C5C(=C4)C(=O)N(CCO)C(=O)C5=C6N#CC=C6)C=C3</chem> |
| C8.008 |  <chem>CCOC(=O)C1=CC2=C(N1)N=CN=C2SC1C(=O)OC(C)C</chem> |






| | |
|--------|--|
| C8.009 |  |
| C8.010 |  |
| C8.011 |  |
| C8.012 |  |
| C8.013 |  |






| | |
|--------|--|
| C8.014 |  |
| C8.015 |  |
| C8.016 |  |
| C8.017 |  |
| C8.018 |  |





| | |
|--------|---|
| C8.019 |  <p>Chemical structure of a pyrimidine derivative. It features a 4-bromophenyl group attached to a furan ring, which is linked via a vinyl bridge to a pyrimidine ring. The pyrimidine ring has a cyano group at position 2 and a 2-oxo-1,2,3,4-tetrahydropyrimidin-5-yl group at position 4.</p> |
| C8.020 |  <p>Chemical structure of a pyrimidine derivative. It features a phenyl group attached to a pyrimidine ring, which is linked via a vinyl bridge to a furan ring. The pyrimidine ring has a carbonyl group at position 2 and a morpholine ring at position 4.</p> |
| C8.021 |  <p>Chemical structure of a pyrimidine derivative. It features a methoxy group attached to a pyrimidine ring, which is linked via a carbonyl group to a carbamate group.</p> |
| C8.022 |  <p>Chemical structure of a pyrimidine derivative. It features a trifluoromethyl group attached to a pyrimidine ring, which is linked via a carbonyl group to a morpholine ring.</p> |
| C8.023 |  <p>Chemical structure of a pyrimidine derivative. It features a dimethylamino group attached to a pyrimidine ring, which is linked via a carbonyl group to a carbamate group.</p> |





| | |
|--------|--|
| C9.001 |  <chem>Clc1ccc(cc1)C(=O)N/C=C/c2ccoc2C(=O)N3CCCCC3C</chem> |
| C9.002 |  <chem>O=C/C=C/c1ccoc1C(=O)c2ccccc2</chem> |
| C9.003 |  <chem>Cc1cc(C)cc(C(=O)N2C(=O)C(=O)N2C(=O)/C=C/c3ccoc3)cc1</chem> |
| C9.004 |  <chem>COc1cc(C)cc(C(=O)N2C(=O)C(=O)N2C(=O)/C=C/c3ccoc3)cc1</chem> |
| C9.005 |  <chem>CC1=CC=C(C=C1)C(=O)N/C=C/c2ccoc2C(=O)N(C)C</chem> |

| | |
|---------|---|
| C9.006 |  |
| C10.003 |  |
| C10.005 |  |
| C10.012 |  |
| C10.015 |  |

| | |
|---------|--|
| C11.001 |  <chem>CN(C)C(=O)O[N+]1=C(C)C(OC)C=C1</chem> |
| C11.002 |  <chem>CN(C)C(=O)O[N+]1=C(C)C=C(CN(C)C)C=C1</chem> |
| C12.001 |  <chem>COc1ccc(cc1)N2C(=O)c3ccc(cc3C2=O)Oc4ccc(cc4)Oc5ccc(cc5)N6C(=O)c7cc(ccc7C6=O)C(=O)O</chem> |
| C13.001 |  <chem>c1ccc(cc1)N2C(=S)N(Cc3c[nH]c4ccccc34)C2=O</chem> |
| C13.002 |  <chem>CN(C)C(=O)O[N+]1=C(C)C(OC)C=C1C</chem> |

| | |
|---------|--|
| C15.004 |  |
| C16.001 |  |
| C16.003 |  |
| C16.004 |  |
| C16.005 |  |

| | |
|---------|--|
| C16.006 |  |
| C16.007 |  |
| C16.008 |  |
| C16.009 |  |

| | |
|---------|---|
| C16.010 |  |
| C16.011 |  |
| C16.012 |  |
| C16.013 |  |

80. (new) A method of inhibiting an activity of at least one enzyme selected from alanyl aminopeptidases, dipeptidyl peptidase and analogous enzymes in a subject in need thereof, wherein the method comprises administering to the subject at least one of a composition of claim 78 and an active ingredient thereof in an amount sufficient for inhibiting the activity of the at least one enzyme.

81. (new) A method of inhibiting an activity of at least one enzyme selected from alanyl aminopeptidases, dipeptidyl peptidase and analogous enzymes in a subject in need thereof, wherein the method comprises administering to the subject at least one of a composition of claim 79 and an active ingredient thereof in an amount sufficient for inhibiting the activity of the at least one enzyme.

82. (new) A method of topically influencing an activity of at least one enzyme selected from alanyl aminopeptidases, dipeptidyl peptidase and analogous enzymes in a subject in need thereof, wherein the method comprises topically administering to the subject at least one of a composition of claim 78 and an active ingredient thereof in an amount sufficient for influencing the activity of the at least one enzyme.

83. (new) A method of topically influencing an activity of at least one enzyme selected from alanyl aminopeptidases, dipeptidyl peptidase and analogous enzymes in a subject in need thereof, wherein the method comprises topically administering to the subject at least one of a composition of claim 79 and an

active ingredient thereof in an amount sufficient for influencing the activity of the at least one enzyme.

84. (new) A method of preventing or treating at least one condition selected from multiple sclerosis, Morbus Crohn, Colitis ulcerosa, rheumatoid arthritis, diabetes type I, autoimmune thyroid gland diseases, Morbus Wegener, systemic Lupus erythematosus visceralis and other autoimmune diseases; inflammatory diseases; allergic asthma bronchiale, allergic rhinitis, food allergy, atopic eczema, contact dermatitis, urticaria, angioedema and other allergic diseases; rejection of allogenic or xenogenic transplanted organs, tissues and cells such as, e.g. kidney, heart, liver, pancreas, skin or stem cell transplants; graft-versus-host diseases; skin and mucosa diseases such as, e.g., psoriasis, and acne; dermatological diseases associated with a hyperproliferation and changed differentiation states of fibroblasts (*inter alia*, benign fibrosing and sclerosing skin diseases and malign fibroblastar hyperproliferation states); acute neuronal diseases, in particular ischemia-caused cerebral damages after an ischemic or hemorrhagic stroke, cranio-cerebral trauma, cardiac arrest, myocardial infarction or as a consequence of heart surgery; chronic neuronal diseases, in particular Morbus Alzheimer, Pick's disease, Progressive Supranuclear Palsy, cortical degeneration, frontotemporal dementia, Morbus Parkinson, Morbus Huntington, prion-caused diseases and amyotrophic lateral sclerosis; chronic obstructive pulmonal diseases (COPD); prostata carcinoma and other tumors as well as metastases; Heavy Acute Respiratory Syndrome (SARS); and sepsis and sepsis-

like conditions in a subject in need thereof, wherein the method comprises administering to the subject at least one of a composition of claim 78 and an active ingredient thereof in an amount sufficient for preventing or treating the at least one condition.

85. (new) A method of preventing or treating at least one condition selected from multiple sclerosis, Morbus Crohn, Colitis ulcerosa, rheumatoid arthritis, diabetes type I, autoimmune thyroid gland diseases, Morbus Wegener, systemic Lupus erythematosus visceralis and other autoimmune diseases; inflammatory diseases; allergic asthma bronchiale, allergic rhinitis, food allergy, atopic eczema, contact dermatitis, urticaria, angioedema and other allergic diseases; rejection of allogenic or xenogenic transplanted organs, tissues and cells such as, e.g. kidney, heart, liver, pancreas, skin or stem cell transplants; graft-versus-host diseases; skin and mucosa diseases such as, e.g., psoriasis, and acne; dermatological diseases associated with a hyperproliferation and changed differentiation states of fibroblasts (*inter alia*, benign fibrosing and sclerosing skin diseases and malign fibroblastar hyperproliferation states); acute neuronal diseases, in particular ischemia-caused cerebral damages after an ischemic or hemorrhagic stroke, cranio-cerebral trauma, cardiac arrest, myocardial infarction or as a consequence of heart surgery; chronic neuronal diseases, in particular Morbus Alzheimer, Pick's disease, Progressive Supranuclear Palsy, cortical degeneration, frontotemporal dementia, Morbus Parkinson, Morbus Huntington, prion-caused diseases and amyotrophic lateral sclerosis; chronic obstructive

pulmonal diseases (COPD); prostata carcinoma and other tumors as well as metastases; Heavy Acute Respiratory Syndrome (SARS); and sepsis and sepsis-like conditions in a subject in need thereof, wherein the method comprises administering to the subject at least one of a composition of claim 79 and an active ingredient thereof in an amount sufficient for preventing or treating the at least one condition.

86. (new) A method of preventing or treating at least one condition selected from atherosclerosis, arterial inflammation, reperfusion syndrome and stent restenosis, for example after a percutaneous transluminal angioplasty, in a subject in need thereof, wherein the method comprises administering to the subject at least one of a composition of claim 78 and an active ingredient thereof in an amount sufficient for preventing or treating the at least one condition.

87. (new) The method of claim 86, wherein the method comprises administering the at least one of a composition and an active ingredient thereof by using a stent which is coated with the at least one of a composition and an active ingredient thereof.

88. (new) A stent which is coated with at least one of a composition of claim 78 and an active ingredient thereof.

89. (new) A method of preventing or treating at least one condition selected from atherosclerosis, arterial inflammation, reperfusion syndrome and stent restenosis, for example after a percutaneous transluminal angioplasty, in a subject in need thereof, wherein the method comprises administering to the subject at least one of a composition of claim 79 and an active ingredient thereof in an amount sufficient for preventing or treating the at least one condition.

90. (new) The method of claim 89, wherein the method comprises administering the at least one of a composition and an active ingredient thereof by using a stent which is coated with the at least one of a composition and an active ingredient thereof.

91. (new) A stent which is coated with at least one of a composition of claim 79 and an active ingredient thereof.

92. (new) A method of preventing or treating an inflammation reaction at, or caused by, a medical device implanted into an organism, wherein the method comprises administering to the organism at least one of a composition of claim 78 and an active ingredient thereof in an amount sufficient for preventing or treating the inflammation reaction.

93. (new) The method of claim 92, wherein the method comprises administering the at least one of a composition and an active ingredient thereof

at least one of as a coating or layer on the medical device and incorporated in the medical device.

94. (new) The method of claim 92, wherein the method comprises administering the at least one of a composition and an active ingredient thereof by at least one of a local and a systemic administration successively or concurrently.

95. (new) A method of preventing or treating an inflammation reaction at, or caused by, a medical device implanted into an organism, wherein the method comprises administering to the organism at least one of a composition of claim 79 and an active ingredient thereof in an amount sufficient for preventing or treating the inflammation reaction.

96. (new) The method of claim 95, wherein the method comprises administering the at least one of a composition and an active ingredient thereof at least one of as a coating or layer on the medical device and incorporated in the medical device.

97. (new) The method of claim 95, wherein the method comprises administering the at least one of a composition and an active ingredient thereof by at least one of a local and a systemic administration successively or concurrently.